BREAKING: Moderna says its COVID-19 vaccine safe for children as young as six months old after ‘successfully’ completing clinical trial
- Moderna announced Wednesday that it had completed Phase 2 and 3 clinical trials for its vaccine in children as young as six months old
- The company hopes to have the shot available to the youngest of children as early as this summer
Moderna announced Wednesday morning that it has successfully completed clinical trials for its COVID-19 vaccine in children as young as six months old and soon plan to submit data to regulators to get its jab approved.
The Phase 2 and 3 trials were recently completed and included the six months to two years old age group, and the two to six years old groups. Both receive tow 25 microgram vaccine doses.
The Cambridge, Massachusetts-based company hopes to have its shot available for young children as early as this summer.
Moderna’s vaccine is currently only approved for adults 18 and older, and has run into trouble – especially overseas – due to concerns of myocarditis forming in recipients under the age of 30.
‘Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible,’ Stephane Bancel, CEO of the company, said in a statement.
If approved, Moderna could pull out an unlikely victory in the race against Pfizer to get its vaccine approved for children under the age of five years old.
Pfizer’s shot is currently the only one in America authorized for children, with those as young as five years old eligible, while only adults can get the Moderna shot.